CURED INC.

  CURED's first oncology candidate targets the novel malignant tumor antigen EVA1(Myelin Protein Zero-Like 2). This candidate is an immune therapy that aggressively attacks solid tumors seen in pancreatic, hepatic, ovarian, urinary, respiratory and breast cancers. CURED is the only biopharmaceutical company developing CARs or ADCs targeting EVA1 for the treatment of solid tumors.

  CURED's lead CAR product incorporates a composite co-stimulatory domain of the B cell signaling moiety, CD79A/CD40, to induce a nuclear translocating signal, NF-κB, to synergize with other T cell signals and improve CAR-T cell function. In addition, short hairpin RNA is incorporated to inhibit the expression of a ubiquitination-related molecule identified by genome-wide CRISPR-Cas9 screening. These constructs endow CAR-T cells with enhanced proliferative capacity and improved anti-tumor efficacy to overcome the immunosuppressive tumor microenvironment seen in solid tumors.

  CURED believes that these novel CAR-T cells could serve as a cell therapy platform beyond oncologic diseases because the CAR structure is designed based on topologically rational theories to exert longer persistence and more powerful cytotoxicity than empirically designed CAR based on well-known diagnostic tumor markers.

  CURED's second CAR product targets NKp44L that is abundantly expressed on malignant cells. CURED is focused on the development of CAR-T cells that efficiently destroy osteosarcoma, rhabdomyosarcoma and glioblastoma.

  The Company is also developing donor-derived or cell line-based allogeneic CAR-T/CAR-NK cells for the creation of an off-the-shelf cell therapy.